Treatment Action Group
By
Treatment Action Group
Published: Jan. 25, 2021, 1:33 a.m.·
Tags:
Advocacy
On 21 January 2021, Treatment Action Group and partners conducted a webinar on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and advanced HIV disease (AHD).
Read More →
By
Treatment Action Group
Published: Dec. 16, 2020, 6:46 p.m.·
Tags:
Advocacy
TB and viral hepatitis co-infections and advanced HIV disease (AHD) put the lives of people living with HIV at risk, and interventions to address these must be prioritized by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and reflected in its funding allocations. The development of FY2021 Country Operational Plans (COPs) provides a critical opportunity for advocates to ensure that the latest developments in preventing, diagnosing, and treating co-infections and AHD are implemented within PEPFAR programs.
Read More →
By
Treatment Action Group,
Stop TB Partnership
Published: Dec. 8, 2020, 11:18 p.m.·
Tags:
Global TB response,
Research and development,
Advocacy
The report — Tuberculosis Research Funding Trends, 2005–2019 — presents new data on 2019 funding for TB research and development and analyzes trends in investment since 2005.
Read More →
By
Treatment Action Group
Published: Nov. 17, 2020, 3:26 p.m.·
Tags:
Treatment,
Prevention,
Diagnostics,
Vaccines
Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.
Read More →
By
Treatment Action Group
Published: Sept. 23, 2020, 1:57 a.m.·
Tags:
TB care,
Advocacy
Read More →
By
Treatment Action Group
Published: Sept. 21, 2020, 1:09 p.m.·
Tags:
Diagnostics,
Research and development,
Access,
Advocacy
Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
Read More →
By
Treatment Action Group
Published: Sept. 18, 2020, 1:27 p.m.·
Tags:
Medicines,
Research and development,
Access,
Advocacy
PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.
Read More →
By
Treatment Action Group
Published: Sept. 8, 2020, 2:11 p.m.·
Tags:
Global health,
Global TB response,
Research and development,
Advocacy
Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.
Read More →
By
Treatment Action Group,
OTMeds
Published: Aug. 3, 2020, 8:04 p.m.·
Tags:
Prevention,
Advocacy
TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.
Read More →
By
Treatment Action Group
Published: July 28, 2020, 6:03 p.m.·
Tags:
Drug-resistant TB,
Diagnostics,
Advocacy
Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.
Read More →
Page 1 of 17 · Total posts: 10
1
2
Last→